William Damsky, PhD
Dermatology · New Haven, CTNPI 1871938381
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,685 of the $22,927 with a category attached, or 64.0%. 12 manufacturers reported payments, led by Incyte Corporation at 40.8% of the total. Reporting peaked in 2024 at $9,429 and has fallen 99.5% since, to $48 in 2025.
Across 34 payments — averaging $674.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$9K
- Pfizer$6K
- Fresenius Kabi USA, LLC$3K
- Boehringer Ingelheim$2K
- Sanofi-aventis U.S. LLC$1K
- Vertex$393
- plus $514 from 6 others
Across 6 payments — averaging $168,099 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$994K
- E.r. Squibb & Sons, L.L.C.$15K
What the payments were for
- Consulting fees$14,68564%
- Speaking & faculty fees$6,00026%
- Travel & lodging$1,1505%
- Food & beverage$1,0114%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 13 | $9,361 |
| Pfizer | 4 | $6,164 |
| Fresenius Kabi USA, LLC | 2 | $2,934 |
| Boehringer Ingelheim | 2 | $2,490 |
| Sanofi-aventis U.S. LLC | 2 | $1,071 |
| Vertex | 1 | $393 |
| Regeneron | 4 | $159 |
| Regeneron Healthcare Solutions, Inc. | 2 | $151 |
| Lilly USA, LLC | 1 | $83 |
| Sanofi | 1 | $66 |
| Novartis | 1 | $42 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,927 in reported general payments places this provider in the 85th percentile of 222 dermatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 161 | $593,792 |
| Humira(Cf) PenAdalimumab | 23 | $307,433 |
| OlumiantBaricitinib | 50 | $247,723 |
| RinvoqUpadacitinib | 27 | $170,316 |
| Dupixent SyringeDupilumab | 16 | $118,357 |
| AdbryTralokinumab-Ldrm | 24 | $92,530 |
| XeljanzTofacitinib Citrate | 15 | $84,148 |
| OtezlaApremilast | 16 | $77,050 |
| OpzeluraRuxolitinib Phosphate | 19 | $71,000 |
| Clobetasol Propionate | 143 | $3,829 |
| Tacrolimus | 18 | $3,820 |
| Acitretin | 20 | $3,799 |
| Minoxidil | 104 | $1,867 |
| Fluocinolone Acetonide | 11 | $1,325 |
| Fluorouracil | 21 | $1,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlumiant | $83 | $247,72350 claims |
| PfizerXeljanz | $6,164 | $84,14815 claims |
| Incyte CorporationOpzelura | $9,361 | $71,00019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 dermatology providers in Connecticut.
Other dermatology in New Haven
- Christopher BunickNew Haven$661K
- Keith ChoateNew Haven$362K
- David LeffellNew Haven$94K
- Mariam TotonchyNew Haven$52K
- Lisa DonofrioNew Haven$38K
- Richard AntayaNew Haven$37K
- Leonard MilstoneNew Haven$31K
- Michael GirardiNew Haven$20K
- Jeffrey CohenNew Haven$18K
- Mary TomaykoNew Haven$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.